News

Platelet Response to Increased Aspirin Dose in Patients Whose Platelets were Non-Responsive to Lower Aspirin Doses (Encore)

Posted on: 12/05/2011

F. Gengo; M.Rainka; E. Westphal; M. Robson; M. Hourihane; V. Bates

The Journal of Clinical Pharmacology; September 2010 :

The most common aspirin dose for secondary stroke prophylaxis is 81 mg daily though current FDA guidelines suggest doses between 50 and 325 mg daily. Recent data from our group indicate an overall prevalence of platelet non-responsiveness to aspirin to be 20%.

The purpose of this study is to determine what percentage of patients who do not respond to aspirin 81 mg daily are truly aspirin resistant at any reasonable dose compared to those in whom 81 mg daily may simple be too low of a dose.